Actor and author Henry Winkler, Apellis Pharmaceuticals spokesperson for its “GA Won’t Wait” geographic atrophy (GA) disease awareness campaign.

April 17, 2023 12:36 PM EDTUpdated 02:40 PM

Marketing

Apellis raises uncommon eye disease profile with ‘The Fonz’ actor Henry Winkler

Beth Snyder Bulik

Senior Editor

Sometimes celebrities are caregivers too. Actor and author Henry Winkler, best known for his ‘70s TV role as “The Fonz,” fits that description and is now speaking up about an advanced form of macular degeneration after his experience with his father-in-law.

Winkler is working with Apellis Pharmaceuticals as spokesman for its “GA Won’t Wait” geographic atrophy (GA) disease awareness campaign beginning with media interviews and social posts but expanding to include TV and radio ads later this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Apellis raises uncommon eye disease profile with ‘The Fonz’ actor Henry Winkler

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

Bristol Myers’ lead deal negotiator to depart after inking series of multibillion-dollar acquisitions

Three big winners from AbbVie's $8.7B Cerevel deal: A drugmaker, a CEO and a SPAC

The Endpoints 100 survey: Has biotech hit rock bottom?

Early prediction of outcomes in DLBCL clinical trials through MRD testing

Apel­lis rais­es un­com­mon eye dis­ease pro­file with ‘The Fonz’ ac­tor Hen­ry Win­kler

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win ...

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

Bris­tol My­ers’ lead deal ne­go­tia­tor to de­part af­ter ink­ing se­ries of multi­bil­lion-dol­lar ac­qui­si­tions

Three big win­ners from Ab­b­Vie's $8.7B Cerev­el deal: A drug­mak­er, a CEO and a SPAC

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

Apellis raises uncommon eye disease profile with ‘The Fonz’ actor Henry Winkler

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

Bristol Myers’ lead deal negotiator to depart after inking series of multibillion-dollar acquisitions

Three big winners from AbbVie's $8.7B Cerevel deal: A drugmaker, a CEO and a SPAC

The Endpoints 100 survey: Has biotech hit rock bottom?

Early prediction of outcomes in DLBCL clinical trials through MRD testing